Sign up for a free trial now
  • Login
  • Subscribe
  • Take a FREE Trial
  • About Us
  • Contact us
  • RSS

21 May 2013


The Pharma Letter
  • Home
  • 7 Day Premium Trial
  • Pharmaceuticals
  • Biotechnology
  • Generics
  • Events
  • Companies
  • Drugs
  • Subscribe

Spironolactone Articles

Spearmint tea: remedy for female body hair

5 March 2007

Actavis launches five new products in USA

17 July 2006

Japan stock market week to September 5

12 September 2005

Stock Commentary - Tokyo week to Sept 5

12 September 2005

Encouraging results for AstraZeneca on Exanta and Atacand

8 September 2003

War, terror and terroism overshadow normally sanguine FDLI meeting

21 April 2003

2002's crop of new product launches backs up R&D fears

10 February 2003

New guidance for CHF treatment aims at non-cardiologists

4 September 2001

Faulding sales rise 17.5%, boosted by pharma

9 August 2001

India raises prices of 14 formulations

20 March 2001

Market forecasts for arrythmia, CHD drugs

29 November 2000

Actelion well-placed for success with endothelin antagonists for heart

21 September 2000

Generic spironolactone in USA

3 August 1999

NEJM reports 30% mortality reduction with new CV drug regimen

20 July 1999

A paradigm shift in chronic heart failure management by Mark Greener

7 May 1999

Searle's Aldactone Effective In Heart Failure

19 November 1998

Showing 1-16 of 16 articles

Go to beginningPrevious
  • 1
NextGo to end
  • Hot Topics
  • Most Read
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
  • Elan makes "transformational" acquisitions and a divestment
  • Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
  • SciClone gains China rights to Zensun's Neucardin
  • Bristol-Myers' data on Yervoy and nivolumab causes a stir
  • Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member

30 Day Premium Trial


Events

Twitter Right banner

RSS



© 2013 thepharmaletter.com

  • Home
  • RSS
  • About Us
  • Subscribe
  • Terms and Conditions
  • Article Archive
Site powered by WORKSsitebuilder CMS